It’s time to reconsider and maybe revoke the approval of Acadia Pharmaceuticals’ (ACAD) antipsychotic drug Nuplazid.
The San Diego-based drug maker has run four randomized, placebo-controlled Phase 3 clinical trials of Nuplazid and managed to demonstrate a statistically significant reduction in hallucinations and psychotic symptoms in only one of them.
Three of these clinical trials failed, including a study involving schizophrenia patients that Acadia announced on Monday night.
About the Author Reprints
